Results 211 to 220 of about 1,359,668 (353)

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Dual GSK3β/SIRT1 modulators for Alzheimer's: mechanisms, drug discovery and future perspectives. [PDF]

Front Pharmacol
Kareem AI, Kapp E, Joubert J, Zou X.
europepmc   +1 more source

Targeting of myosin light chain kinase in vasculr smooth muscle cells, and its implication for the drug discovery

, 2000
Kazuhiro Kohama
openalex   +2 more sources

Only the strong survive: therapeutic selective pressure drives medulloblastoma leptomeningeal metastasis

Molecular Oncology, EarlyView.
Radiation therapy induces cancer cell death and immune cell infiltration, mainly monocytes, macrophages, and dendritic cells. Elevated serum cytokine levels and disruption of the blood–brain barrier promote leptomeningeal dissemination. Cotreatment with dexamethasone reduces cytokine levels, preserves barrier integrity, and limits metastatic spread ...
Francis Y. He, Adrienne Boire
wiley   +1 more source

AI-Driven Polypharmacology in Small-Molecule Drug Discovery. [PDF]

Int J Mol Sci
Abdelsayed M.
europepmc   +1 more source

Role of drug metabolism in drug discovery and development [PDF]

, 2001
Gondi Kumar, Sekhar Surapaneni
openalex   +1 more source

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis

Molecular Oncology, EarlyView.
This study highlights the potential of automated enumeration using the ACCEPT software to refine circulating tumor cell (CTC) detection in metastatic colorectal cancer (mCRC). The automated method demonstrates improved accuracy and reduced variability compared to the manual approach.
Michela De Meo, Marco Siringo, Alessandro Vici, Ann Zeuner, Orietta Gandini, Paola Gazzaniga, Chiara Nicolazzo   +6 more
wiley   +1 more source

Pseudonatural Products for Chemical Biology and Drug Discovery. [PDF]

J Med Chem
Greiner LC, Pahl A, Heinzke AL, Zdrazil B, Leach AR, Young RJ, Leeson PD, Waldmann H.   +7 more
europepmc   +1 more source

Drug Discovery and Development

JACS Au
Carole Duboc, Sabine L. Flitsch
openaire   +3 more sources

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source